News about Global Pharma

Made Scientific, Hemogenyx Partner to Advance CAR-T Cell Therapy for AML

Made Scientific and Hemogenyx Pharmaceuticals have announced a technology transfer and manufacturing partnership to advance HG-CT-1, an autologous CAR-T cell therapy for acute myeloid leukaemia (AML).

Global Pharma | 09/09/2025 | By Mrinmoy Dey |  173

Novartis to Acquire Tourmaline Bio for USD 48 per share

Novartis to acquire Tourmaline Bio in a USD 1.4 billion deal, gaining rights to pacibekitug—an anti-IL-6 antibody with potential in cardiovascular disease; transaction expected to close in Q4 2025.

Global Pharma | 09/09/2025 | By Dineshwori |  298

Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001

Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.

Global Pharma | 09/09/2025 | By Dineshwori |  437

Indegene Expands India Footprint with New Centre in Pune

Indegene, a digital-first life sciences commercialisation company, has expanded its India footprint with the launch of a new centre in Pune.

Global Pharma | 08/09/2025 | By Mrinmoy Dey |  240

Servier to Acquire KER-0193 from Kaerus Bioscience in Deal Worth Up to USD 450 Million

Servier has signed a definitive agreement to acquire KER-0193 from Kaerus Bioscience, a potential first-in-disease treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder.

Global Pharma | 08/09/2025 | By Mrinmoy Dey |  407

Ronovo Surgical Closes Series D Financing

Ronovo Surgical secures USD 67 million in Series D funding led by JJDC, raising over USD 100 million in 2025 to advance minimally invasive surgery.

Global Pharma | 06/09/2025 | By Dineshwori |  285

Hengrui Pharma Grants Braveheart Bio Exclusive Global Rights to Cardiac Myosin Inhibitor HRS-1893

Hengrui Pharma has signed an exclusive licensing deal with US-based Braveheart Bio for its Phase 3-ready cardiac myosin inhibitor HRS-1893. Braveheart will make an upfront payment of USD 65 million and a near-term payment of up to USD 10 million upon technology transfer completion, totalling USD 75 million.

Global Pharma | 06/09/2025 | By Mrinmoy Dey |  643

Clearpoint Prism Neuro Laser Therapy System Receives FDA Clearance for 1.5T MRI Use

ClearPoint Neuro has announced that its ClearPoint Prism Neuro Laser Therapy System has received 510(k) clearance from the US FDA for use under 1.5T MRI guidance, in addition to its previously cleared 3T MRI compatibility.

Global Pharma | 06/09/2025 | By Dineshwori |  494

Cipla launches HUENA, maiden non-antibiotic drug in India for recurring UTIs

With HUENA, Cipla becomes the first in India to offer Methenamine Hippurate, a non-antibiotic therapy for recurrent UTIs, strengthening its fight against AMR.

Global Pharma | 06/09/2025 | By Dineshwori |  182

Arrowhead and Novartis Sign Global License and Collaboration Deal

Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.

Global Pharma | 05/09/2025 | By Dineshwori |  288